RNA mapping project focuses on inflammatory bowel disease
Scientists at the Wellcome Sanger Institute in collaboration with Pacific Biosciences (PacBio) have launched a new initiative to map how gene activity shapes the immune system.
It is hoped that the project will identify new therapeutic targets for conditions such as inflammatory bowel disease (IBD).
The scientists will apply long-read single-cell RNA sequencing to nearly 1,500 blood and gut tissue samples from three ongoing studies, to capture the extent to which genes are expressed and which isoforms of each gene are used.
The approach will provide high-resolution maps of RNA expression and splicing across different cell types, tissues, and individuals, which could reveal why some treatments work better for certain people.
Two of these ongoing studies, IBDverse and IBD-Response, aim to uncover new ways to treat IBD. By sequencing cells from individuals both with and without the condition, researchers hope to identify RNA isoforms linked to IBD susceptibility, progression, and response to treatment.
Dr Carl Anderson, Interim Head of Human Genetics at the Wellcome Sanger Institute, said: “Long-read sequencing gives us the chance to look at gene activity in much greater detail than before. By applying this technology at scale, we hope to uncover biological differences that could explain why some people respond better to treatments for conditions like IBD than others. IBD affects many lives, and current therapies don’t work for everyone. This project could help us understand why and open new directions for more effective, personalised treatment.”
The third, Project JAGUAR, is a large-scale collaboration across seven Latin American countries that explores how genetic diversity shapes immune responses. Samples from Peru and Mexico will be analysed, bringing valuable insights into how ancestral diversity shapes isoform variation and immune responses.
The value of long-read RNA sequencing
Unlike DNA sequencing, which reveals changes in the genetic code itself, RNA sequencing offers a dynamic snapshot of which genes are active and the level of activity in any given tissue sample or cell.
Short-read sequencing has enabled researchers at the Sanger Institute to generate detailed maps of gene expression across many thousands of samples, helping reveal which genes are switched on or off in different tissues and health conditions. However, short reads cannot fully capture the diversity of RNA isoforms.
Once published, the datasets generated through this project will be made openly available to the global scientific community, providing a valuable resource to advance research in IBD and immunology.
The team will also share their technical insights and develop new computational methods to support the efficient analysis of long-read single-cell RNA data.
Christian Henry, President and Chief Executive Officer of PacBio, said: “At PacBio, we believe the most meaningful science happens when technology serves a clear purpose. This collaboration with the Sanger Institute brings that vision to life, using HiFi long-read sequencing to uniquely capture the full isoform landscape at single-cell resolution and at scale. It is a powerful example of how accuracy and completeness can reveal new insights into immune function, IBD progression, and treatment response.”
Diana Spencer, Senior Digital Content Editor, DDW
